Newbury Pharmaceuticals announced the successful enlargement of the portfolio with the addition of Levodopa/Benserazide tablets. Regulatory filling will take place in the near future, and aim to launch this medicine in Sweden where the total annual value of the market is estimated to be EUR 4 million according to DLMI Nordic Pharma Insights. Newbury currently has over thirty (30) products in its portfolio and the first launches took place in 2022 with additional launches planned in a steady stream over the coming years.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.22 SEK | +0.62% |
|
0.00% | +4.89% |
04-10 | Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 | CI |
02-22 | Newbury Pharmaceuticals Secures SEK9 Million Sales Order | MT |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+4.89% | 7.41M | |
-12.59% | 8.23B | |
+26.58% | 1.26B | |
-13.82% | 339M | |
+0.36% | 267M | |
+8.33% | 220M | |
-45.37% | 82.2M | |
-18.35% | 78.45M | |
+26.03% | 62.1M |
- Stock Market
- Equities
- NEWBRY Stock
- News Newbury Pharmaceuticals AB
- Newbury Pharmaceuticals Strengthens its Portfolio with Levodopa/Benserazide